Cisco,
In response to this post and the following, thanks for the timely information.
I did read about the reorganization which in my opinion is very good for the company. Also the renwal of the credit line. These are positive steps which should make LCA-Vision a leader in the Eximer Eye Care business.
I don't know where your entry point was or how many shares you bought, but you should be able to recoup your losses in time. As I have remarked in past posts on this thread, LCAV will increase in price in time as the company gets into a profit position.
As for the current technical picture, the current price support is $2.625; resistance $3.375; short term momentum (MM) buy; intermediate MM hold; long term MM nuetral; stochastics buy; OBV negative.
This stock is in the accumulation phase, and is currently forming the second leg of a "W" pattern. The only factor not supporting a breakout to a positive trend is volume. The stock price must breakout above $4.00/sh. to continue its upward movement.
If you have a long "time horizon", purchase of this issue at these prices will be rewarded. Be aware as I'm sure that you are, that Eximer Eye Care stocks are not doing that well at the present time. But when this group does gain public and institutional support, LCAV will be the leader.
Appreciate your comments and questions. I will continue to monitor LCAV and advise the thread as conditions warrant.
Regards,
Harry |
